Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 5, 2020

Primary Completion Date

May 12, 2020

Study Completion Date

July 9, 2020

Conditions
Corona Virus Disease 2019(COVID-19)
Interventions
BIOLOGICAL

UC-MSCs

3 does of UC-MSCs(4.0\*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.

BIOLOGICAL

Saline containing 1% Human serum albumin(solution without UC-MSCs)

3 does of placebo(intravenously at Day 0, Day 3, Day 6)

Trial Locations (3)

430000

General Hospital of Central Theater Command, Wuhan

Maternal and Child Hospital of Hubei Province, Wuhan

Wuhan Huoshenshan Hospital, Wuhan

All Listed Sponsors
collaborator

Huoshenshan Hospital

OTHER

collaborator

Maternal and Child Health Hospital of Hubei Province

OTHER

collaborator

The General Hospital of Central Theater Command

OTHER

collaborator

Vcanbio Cell and Gene Engineering Corp., Ltd.

INDUSTRY

lead

Beijing 302 Hospital

OTHER

NCT04288102 - Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter